Fulcrum Therapeutics FULC, a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter’s loss is pinned at ...
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease ...
Fulcrum Therapeutics reports promising Phase 1b data for pociredir in sickle cell disease and a strong cash position to fund development into 2029, boosting investor confidence.
Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn ...
Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results